Replies to post #144180 on Biotech Values

[DewDiligence]

Re: Bristol Hep C Trial Change Has Big Implications

Thanks for posting that. It’s too soon to say for sure, but this could be a harbinger of a major reset in the thinking about dual-oral HCV regimens.

[DewDiligence]

BMY reports SVR12 data for Daclatasvir+Asunaprevir (without ribavirin) in prior null responders with genotype-1b:

http://finance.yahoo.com/news/investigational-hepatitis-c-dual-daa-214500427.html

…the DCV/ASV Dual regimen achieved SVR12 in 78% (14/18) and 65% (13/20) of GT1b patients when asunaprevir was dosed twice daily…or once daily, respectively.

The above data come from two arms of a 5-arm trial that included various 24-week treatment regimens for genotype-1a and -1b, as explained in the PR.